Hepatitis C (HCV)

Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk

Prophylaxis of Complications of Basic Therapy Using Naderin in Socially Significant Diseases

Hepatitis C Pharmacist, Physician, Patient Navigator Collaborative Care Model in Permanent Supportive Housing

Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs

Combating Related Epidemics in HCV

Persuasive Health Communication Intervention for HIV/HCV

Implementing Low-Barrier HCV Treatment in a Jail Setting

Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic

Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)

Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France

Accupower ® HCV Performance Evaluation Quant Kit Bioneer Existation™FA 96/384

Lay User Evaluation of the Panbio™ HCV Self-Test

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554

Acupuncture as an Adjunctive Treatment for Hepatitis C Patients